1
|
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
|
Nat Genet
|
2007
|
19.18
|
2
|
A common inversion under selection in Europeans.
|
Nat Genet
|
2005
|
13.66
|
3
|
A common variant associated with prostate cancer in European and African populations.
|
Nat Genet
|
2006
|
13.47
|
4
|
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.
|
Nat Genet
|
2007
|
13.28
|
5
|
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
|
Nat Genet
|
2007
|
12.65
|
6
|
Neuregulin 1 and susceptibility to schizophrenia.
|
Am J Hum Genet
|
2002
|
7.40
|
7
|
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
|
Nat Genet
|
2008
|
6.10
|
8
|
Multiple novel transcription initiation sites for NRG1.
|
Gene
|
2004
|
1.31
|
9
|
Sequences from first settlers reveal rapid evolution in Icelandic mtDNA pool.
|
PLoS Genet
|
2009
|
1.03
|
10
|
A statistical approach to identify ancient template DNA.
|
J Mol Evol
|
2007
|
1.02
|
11
|
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
|
J Pharmacol Exp Ther
|
2007
|
0.91
|
12
|
Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.
|
J Med Chem
|
2009
|
0.90
|
13
|
Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.
|
Bioorg Med Chem Lett
|
2007
|
0.77
|
14
|
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
|
Bioorg Med Chem Lett
|
2004
|
0.75
|
15
|
Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies.
|
J Org Chem
|
2008
|
0.75
|